Navigation Links
QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
Date:8/22/2007

Multicenter Study Enrolls More Than 800 Women to Evaluate QuatRx's

New-Generation Selective Estrogen Receptor Modulator (SERM)

ANN ARBOR, Mich., Aug. 22 /PRNewswire/ -- QuatRx Pharmaceuticals, a privately-held biopharmaceutical company focused on development and commercialization of compounds to treat endocrine, metabolic and cardiovascular disorders, today announced that it has completed enrollment of a pivotal Phase 3 clinical trial of Ophena(TM) (ospemifene), the company's estrogen-free oral therapy in development for the treatment of vaginal symptoms associated with menopause.

Ophena(TM) is a new-generation selective estrogen receptor modulator (SERM) for postmenopausal vaginal syndrome (PVS), a common condition in postmenopausal women sometimes referred to as vaginal atrophy and characterized by vaginal symptoms such as dryness, irritation and sexual pain. Phase 2 clinical trials with Ophena(TM) demonstrated beneficial effects on vaginal epithelium and bone markers. In addition, in a Phase 2 trial, Ophena(TM) did not induce hot flashes in postmenopausal women when compared to placebo.

Patient enrollment for the randomized, double-blind study has reached 827 post-menopausal women at 80 trial centers throughout the United States. Women participating in the study are treated with either a 30- or 60-mg once daily oral dose of Ophena(TM) or placebo for 12 weeks. The study is the first of two pivotal Phase 3 efficacy trials planned for the compound.

"Completion of enrollment for this first Ophena(TM) Phase 3 trial is a significant development milestone," said Robert L. Zerbe, M.D., chief executive officer and president of QuatRx. "In this pivotal study we are seeking to confirm the beneficial vaginal effects already seen in our Phase 2 program. Millions of women suffer from such post-menopausal symptoms for which there are no oral non-estrogen treatments available. Ophena(TM) is specifically designed to address a major unmet
'/>"/>

SOURCE QuatRx Pharmaceuticals Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
2. Celsion Completes Enrollment in Phase I Liver Cancer Study
3. LANI completes Phase I in Japan and to commence Phase I in UK
4. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
5. Monitoring Patient Glucose Levels: New Advances in software make it easier
6. Managing Preanalytical Processes for Patient Safety
7. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
8. Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/32cmct/inferior_vena ) ... Cava (IVC) Filters - Global Trends, Estimates and Forecasts, ... http://photos.prnewswire.com/prnh/20130307/600769 Global Inferior Vena ... million by 2016. The North America ... value while Europe claims approximately ...
(Date:12/15/2014)... BRIDGEWATER, N.J. , Dec. 15, 2014 ... US (EURONEXT: SAN and NYSE: SNY) are collaborating with ... Cholesterol Counts , an awareness program that will ... and the risks associated with high LDL-C (bad cholesterol). ... .com to take a brief poll and answer ...
(Date:12/15/2014)... --  DaVita HealthCare Partners Inc.  (NYSE: ... most innovative health care communities, today announced that ... Research  (DCR) and  HealthCare Partners Clinical Research , will ... research and data analytics services, specifically in patients ... disease (ESRD), as well as primary care and ...
Breaking Medicine Technology:Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 2Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 3Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 5Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 6DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 2DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 3DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 4
... Incorporated (Nasdaq: VPHM ) today announced that ... of the European Medicines Agency (EMA) has adopted a ... Authorization (PUMA) for Buccolam® (midazolam, oromucosal solution), for treatment ... and adolescents, from 3 months to less than 18 ...
... serving Virginia patients reduced healthcare-acquired infection rates (HAIs) a ... of $1.2 million in additional costs to the health ... existing federal hand washing protocols, these hospitals improved patient ... patient length-of-stay and unnecessary readmissions. VHHA Services, ...
Cached Medicine Technology:ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union 2ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union 3ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union 4ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union 5Virginia Hospitals Reduce Infections 41% 2Virginia Hospitals Reduce Infections 41% 3
(Date:12/17/2014)... 17, 2014 Project Veritas is releasing ... videos of MIT economist and Obamacare architect Jonathan Gruber ... O’Keefe conducted the interview, which is being distributed on ... was intentional mislabeling in the Affordable Care Act in ... A two-hundred-and-fifty billion dollar per year tax grab. , ...
(Date:12/17/2014)... Alan Mozes HealthDay ... In the world of infectious diseases, one worrisome phenomenon is ... people. The process -- known as zoonosis -- is ... look for signs that an animal-borne disease might make inroads ... just such a development -- and the culprits in this ...
(Date:12/17/2014)... 2014 (HealthDay News) -- Poor students get more fruits and ... study finds. But, the opposite is true for students ... and vegetables at school may give a healthy boost to ... matter what the family income level, students all ate a ... found. The study was published recently in the journal ...
(Date:12/17/2014)... By Alan Mozes ... -- With the holiday party season fast approaching, a new ... and make DUI arrests have fewer drunk drivers on their ... driving laws more vigilantly are better able to deter inebriated ... "Hardly any new laws are being passed regarding drinking ...
(Date:12/17/2014)... Kathleen Doheny HealthDay Reporter ... loss is rampant in America, and work commitment is a ... No. 1 sleep killer," said Dr. Mathias Basner, an assistant ... of Pennsylvania Perelman School of Medicine. A time-use survey ... that work is the main activity exchanged for sleep. Short ...
Breaking Medicine News(10 mins):Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 3Health News:Poor Students Eat Healthier Foods at School, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3
... science at high school has just become a little more ... from the University of Bath have found that a protein ... a cell divides in two. , In research published in ... shown that the protein is essential for building the microtubules ...
... of The Walter and Eliza Hall Institute, Professor Suzanne ... of the 2008 Thomson Scientific Citation Awards announced at ... Scientific, a US-based international information analysis company, states that ... that identifies the average number of citations per paper ...
... Heart Associations Los Angeles Division today will honor John ... in use around the country and one of the ... Harbor-UCLA Medical Center (LA BioMed). , The association will ... Criley and William Koenig, Los Angeles County Emergency Medical ...
... site heralds AAGL commitment to patient education, ... professional,organization of gynecologists interested in endoscopy and minimally,invasive ... and added a,comprehensive patient education section on ... to treat them. The site,continues to provide physician ...
... ... WHITE PLAINS, N.Y., April 3, 2008 Head lice is ... common,cold.(1) There are about 6 to 12 million cases each year,(2) ... days annually.(3),But, now parents can say good-bye to head lice and ...
... April 3, 2008 Mach One,Corporation, http://www.machonecorp.com, ... prior to large scale manufacturing of its ImmunoGam(TM),colostrum ... highly qualified scientist from BioQual spent a week ... technology transfer and,memorializing the protocols for manufacture of ...
Cached Medicine News:Health News:Mitosis gets harder thanks to new gene discovery 2Health News:Professor Suzanne Cory honored with national citation award 2Health News:Pioneer of paramedic model to be honored 2Health News:Pioneer of paramedic model to be honored 3Health News:Women Can Now Learn About Minimally Invasive Gynecologic Treatments at AAGL.org 2Health News:Women Can Now Learn About Minimally Invasive Gynecologic Treatments at AAGL.org 3Health News:Women Can Now Learn About Minimally Invasive Gynecologic Treatments at AAGL.org 4Health News:New Breakthrough Treatment is Tough On Lice But Gentle On Kids 2Health News:New Breakthrough Treatment is Tough On Lice But Gentle On Kids 3Health News:Mach One Corporation Announces Completion of Final Tests Prior to Full Scale Production 2
Compression Bra...
Post-Surgical compression garments...
... The Albumin Cobalt Binding (ACB®) Test is ... Modified Albumin (IMA®) by measuring the cobalt ... serum sample. First identified in the early ... comes in contact with ischemic tissue in ...
... Test is a clinical chemistry assay that ... the cobalt binding capacity of albumin in ... the early 1990s, IMA is produced when ... tissue in the heart. During ischemia, the ...
Medicine Products: